Immune therapy scores big win against lung cancer in study

Associated Press |

CHICAGO (AP) — New research suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common forms of the disease.



One study found using one of these drugs — Merck's Keytruda (kee-TROO-dah) — with usual chemotherapy greatly improved survival for people newly diagnosed with the most common type of cancer that had spread beyond the lungs.

That's a first, and it's expected to quickly set a new standard of care for about 70,000 patients each year in the United States.

Results were discussed Monday at an American Association for Cancer Research conference in Chicago and published by the New England Journal of Medicine.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Singlepoint Inc

SinglePoint Inc is a mobile technology company engaged in mobile payments, mobile giving, and mobile bidding. It operates mobile commerce and communications platform to accept mobile credit card payments.